Understanding how and why an otherwise tumor-restrictive stroma evolves into a tumor-permissive stroma. We believe that therapies restoring the tumor restrictive stroma by normalizing extracellular matrix turnover are the future of clinical cancer research.
The hallmark of a tumor-permissive stroma is a disruption of tissue microarchitecture and altered extracellular matrix (ECM) remodeling. The extracellular matrix alterations in the tumor fuel a vicious cycle of stromal dissemination enriching for cancer-associated fibroblast (CAFs), desmoplasia, immunosuppression and an epithelial-to-mesenchymal transition leading to poor efficacy of interventions.
A patient-centric approach to evaluate extracellular matrix biomarkers in clinical trials with the potential to predict the likelihood of response and elaborate on method-of-action by monitoring direct or "bystander" effect on the extracellular matrix. In contrast to most other liquid biopsies that focus on circulating tumor DNA (ctDNA) or circulating tumor cells (CSCs), at Nordic Bioscience we focus our biomarker efforts on targeting and quantifying post-translational modifications (PTMs) on proteins or peptide fragments in circulation.
Please don't hesitate to contact us if you have any questions or other inquiries.